Quarterly report · Q3
4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥683.0bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥239.1bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥618.0bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥214.7bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥105.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥39.0bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥105.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥39.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.54T | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥475.7bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.22T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.22T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.07T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥163.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥162.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥91.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥53.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥41.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥68.7bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥84.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥107.33 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥40.06 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥93.25 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥107.29 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥40.05 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.21 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.96 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.9% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-12-31 | ¥172m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥2.1bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥127.8bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥13.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥407.7bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥92.0bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥147.3bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥16.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥682.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥121.9bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥186m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥479m |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥113.4bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥358.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥145.5bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥617.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥109.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 653
| Item | Context | Value | Unit |
|---|---|---|---|
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -7072000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -7912000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReportableSegmentsMember | -14984000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReconcilingItemsMember | 306000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration | -14677000000 | JPY |
| Non recurring profit or loss IFRS | CurrentYTDDuration | 463000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 105519000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 2487000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 2288000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 25000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 105743000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第109期第３四半期(自 2023年10月１日 至 2023年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)テルモ株式会社 | |
| Company name in english cover page | FilingDateInstant | TERUMO CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 佐藤 慎次郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(3374)8111(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Text · Plus | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿三丁目20番２号 東京オペラシティタワー 49F | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(6742)8500(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Text · Plus | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E01630 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45430 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)テルモ株式会社 | |
| Filer name in english | FilingDateInstant | TERUMO CORPORATION | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |